Sökning: onr:"swepub:oai:DiVA.org:uu-307293" >
Sequence variation ...
Sequence variation in mature microRNA-608 and benefit from neo-adjuvant treatment in locally advanced rectal cancer patients
-
- Sclafani, Francesco (författare)
- Royal Marsden NHS Fdn Trust, Dept Med, Sutton SM2 5PT, Surrey, England.
-
- Chau, Ian (författare)
- Royal Marsden NHS Fdn Trust, Dept Med, Sutton SM2 5PT, Surrey, England.
-
- Cunningham, David (författare)
- Royal Marsden NHS Fdn Trust, Dept Med, Sutton SM2 5PT, Surrey, England.
-
visa fler...
-
- Lampis, Andrea (författare)
- Inst Canc Res, Dept Mol Pathol, Sutton SM2 5NG, Surrey, England.
-
- Hahne, Jens Claus (författare)
- Inst Canc Res, Dept Mol Pathol, Sutton SM2 5NG, Surrey, England.
-
- Ghidini, Michele (författare)
- Inst Canc Res, Dept Mol Pathol, Sutton SM2 5NG, Surrey, England.
-
- Lote, Hazel (författare)
- Royal Marsden NHS Fdn Trust, Dept Med, Sutton SM2 5PT, Surrey, England.;Inst Canc Res, Dept Mol Pathol, Sutton SM2 5NG, Surrey, England.
-
- Zito, Domenico (författare)
- Inst Canc Res, Dept Mol Pathol, Sutton SM2 5NG, Surrey, England.
-
- Tabernero, Josep (författare)
- Univ Autonoma Barcelona, Vall Hebron Univ Hosp, Dept Med Oncol, Barcelona 08035, Spain.
-
- Glimelius, Bengt (författare)
- Uppsala universitet,Experimentell och klinisk onkologi
-
- Cervantes, Andres (författare)
- Univ Valencia, Biomed Res Inst INCLIVA, Dept Haematol & Med Oncol, Valencia 46010, Spain.
-
- Begum, Ruwaida (författare)
- Royal Marsden NHS Fdn Trust, Dept Med, Sutton SM2 5PT, Surrey, England.
-
- De Castro, David Gonzalez (författare)
- Royal Marsden NHS Fdn Trust, Dept Med, Sutton SM2 5PT, Surrey, England.
-
- Wilson, Sanna Hulkki (författare)
- Royal Marsden NHS Fdn Trust, Dept Med, Sutton SM2 5PT, Surrey, England.
-
- Peckitt, Clare (författare)
- Royal Marsden NHS Fdn Trust, Dept Med, Sutton SM2 5PT, Surrey, England.
-
- Eltahir, Zakaria (författare)
- Royal Marsden NHS Fdn Trust, Dept Med, Sutton SM2 5PT, Surrey, England.
-
- Wotherspoon, Andrew (författare)
- Royal Marsden NHS Fdn Trust, Dept Med, Sutton SM2 5PT, Surrey, England.
-
- Tait, Diana (författare)
- Royal Marsden NHS Fdn Trust, Dept Med, Sutton SM2 5PT, Surrey, England.
-
- Brown, Gina (författare)
- Royal Marsden NHS Fdn Trust, Dept Med, Sutton SM2 5PT, Surrey, England.
-
- Oates, Jacqueline (författare)
- Royal Marsden NHS Fdn Trust, Dept Med, Sutton SM2 5PT, Surrey, England.
-
- Braconi, Chiara (författare)
- Royal Marsden NHS Fdn Trust, Dept Med, Sutton SM2 5PT, Surrey, England.;Inst Canc Res, Dept Canc Therapeut, Sutton SM2 5NG, Surrey, England.
-
- Valeri, Nicola (författare)
- Royal Marsden NHS Fdn Trust, Dept Med, Sutton SM2 5PT, Surrey, England.;Inst Canc Res, Dept Mol Pathol, Sutton SM2 5NG, Surrey, England.
-
visa färre...
-
Royal Marsden NHS Fdn Trust, Dept Med, Sutton SM2 5PT, Surrey, England Inst Canc Res, Dept Mol Pathol, Sutton SM2 5NG, Surrey, England. (creator_code:org_t)
- 2016-07-05
- 2016
- Engelska.
-
Ingår i: Carcinogenesis. - : Oxford University Press (OUP). - 0143-3334 .- 1460-2180. ; 37:9, s. 852-857
- Relaterad länk:
-
https://academic.oup...
-
visa fler...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Single nucleotide polymorphisms (SNPs) in microRNA genes have been associated with colorectal cancer (CRC) risk, survival and response to treatment. Conflicting results are available on the association between rs4919510, a SNP in mature miR-608 and clinical outcome in CRC. Here, we analyzed the association between rs4919510 and benefit from perioperative treatment in a randomised phase II trial of neoadjuvant Capecitabine and Oxaliplatin (CAPOX) followed by chemo-radiotherapy, surgery and adjuvant CAPOX +/- Cetuximab in high-risk locally advanced rectal cancer (LARC). A total of 155/164 (94.5%) patients were assessable. 95 (61.3%) were homozygous for CC, 55 (35.5%) heterozygous (CG) and 5 (3.2%) homozygous for GG. Median follow-up was 64.9 months. In the CAPOX arm the 5-year progression-free survival (PFS) and overall survival (OS) rates were 54.6% and 60.7% for CC and 82.0% and 82.1% for CG/GG, respectively (HR PFS 0.13, 95% CI: 0.12-0.83, P = 0.02; HR OS 0.38, 95% CI: 0.14-1.01, P = 0.05). In the CAPOX-C arm PFS and OS were 73.2 and 82.2%, respectively for CC carriers and 64.6 and 73.1% for CG/GG carriers (HR PFS 1.38, 95% CI: 0.61-3.13, P = 0.44; HR OS 1.34, 95% CI: 0.52-3.48, P = 0.55). An interaction was found between study treatment and rs4919510 genotype for both PFS (P = 0.02) and OS (P = 0.07). This is the first study investigating rs4919510 in LARC. The CC genotype appeared to be associated with worse prognosis compared to the CG/GG genotype in patients treated with chemotherapy and chemo-radiotherapy alone. Addition of Cetuximab to chemotherapy and chemo-radiotherapy in CC carriers appeared to improve clinical outcome.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Sclafani, France ...
-
Chau, Ian
-
Cunningham, Davi ...
-
Lampis, Andrea
-
Hahne, Jens Clau ...
-
Ghidini, Michele
-
visa fler...
-
Lote, Hazel
-
Zito, Domenico
-
Tabernero, Josep
-
Glimelius, Bengt
-
Cervantes, Andre ...
-
Begum, Ruwaida
-
De Castro, David ...
-
Wilson, Sanna Hu ...
-
Peckitt, Clare
-
Eltahir, Zakaria
-
Wotherspoon, And ...
-
Tait, Diana
-
Brown, Gina
-
Oates, Jacquelin ...
-
Braconi, Chiara
-
Valeri, Nicola
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
- Artiklar i publikationen
-
Carcinogenesis
- Av lärosätet
-
Uppsala universitet